CN116829135A - 大麻二酚对睡眠呼吸暂停的治疗 - Google Patents

大麻二酚对睡眠呼吸暂停的治疗 Download PDF

Info

Publication number
CN116829135A
CN116829135A CN202280012395.XA CN202280012395A CN116829135A CN 116829135 A CN116829135 A CN 116829135A CN 202280012395 A CN202280012395 A CN 202280012395A CN 116829135 A CN116829135 A CN 116829135A
Authority
CN
China
Prior art keywords
cbd
sleep
patients
subject
dee
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280012395.XA
Other languages
English (en)
Chinese (zh)
Inventor
J·帕伦博
D·古特曼
T·希布里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zyne Pharmaceutical Co
Original Assignee
Zyne Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zyne Pharmaceutical Co filed Critical Zyne Pharmaceutical Co
Publication of CN116829135A publication Critical patent/CN116829135A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Acoustics & Sound (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Glass Compositions (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
CN202280012395.XA 2021-01-28 2022-01-28 大麻二酚对睡眠呼吸暂停的治疗 Pending CN116829135A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163142835P 2021-01-28 2021-01-28
US63/142,835 2021-01-28
PCT/IB2022/050781 WO2022162621A1 (en) 2021-01-28 2022-01-28 Treatment of sleep apnea with cbd

Publications (1)

Publication Number Publication Date
CN116829135A true CN116829135A (zh) 2023-09-29

Family

ID=80222209

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280012395.XA Pending CN116829135A (zh) 2021-01-28 2022-01-28 大麻二酚对睡眠呼吸暂停的治疗

Country Status (11)

Country Link
US (1) US20240307418A1 (https=)
EP (1) EP4284349A1 (https=)
JP (1) JP2024505212A (https=)
KR (1) KR20230137404A (https=)
CN (1) CN116829135A (https=)
AU (1) AU2022213009A1 (https=)
CA (1) CA3206508A1 (https=)
IL (1) IL304827A (https=)
JO (1) JOP20230169A1 (https=)
MX (1) MX2023008876A (https=)
WO (1) WO2022162621A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2627344A (en) * 2022-12-16 2024-08-21 Kingdom Therapeutics Ltd Cannabinoid based therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8449908B2 (en) 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
CA2760460C (en) 2009-04-28 2019-04-02 Alltranz Inc. Transdermal formulations of cannabidiol comprising a penetration enhancer and methods of using the same
BR112019026877A2 (pt) * 2017-06-19 2020-06-30 Zelda Therapeutics Operations Pty Ltd composições para distúrbios do sono e tratamentos do mesmo
IL278548B2 (en) * 2018-05-11 2025-07-01 Rhodes Tech Inc Pharmaceutical preparations containing dronabinol and sprays containing the same pharmaceutical preparations
WO2019224824A1 (en) * 2018-05-24 2019-11-28 To Pharmaceuticals Llc Cannabis-based compositions for the treatment of autistic spectrum disorders
BR112022004175A2 (pt) * 2019-09-17 2022-05-31 Zynerba Pharmaceuticals Inc Tratamento de encefalopatia de syngap1

Also Published As

Publication number Publication date
EP4284349A1 (en) 2023-12-06
MX2023008876A (es) 2023-09-12
KR20230137404A (ko) 2023-10-04
AU2022213009A1 (en) 2023-08-17
WO2022162621A1 (en) 2022-08-04
JOP20230169A1 (ar) 2023-07-27
IL304827A (en) 2023-09-01
CA3206508A1 (en) 2022-08-04
JP2024505212A (ja) 2024-02-05
US20240307418A1 (en) 2024-09-19

Similar Documents

Publication Publication Date Title
US12508270B2 (en) Treatment of behavioral impairment in developmental and epileptic encephalopathy
US20240009210A1 (en) Cannabidiol for the Treatment of Refractory Seizures
Freire et al. Treatment of moderate obstructive sleep apnea syndrome with acupuncture: a randomised, placebo-controlled pilot trial
MD3746126T2 (ro) Metode și compoziții pentru tratamentul apneei în somn sau sforăitului simplu
Cereghino Identification and treatment of acute repetitive seizures in children and adults
US20230310364A1 (en) Compositions and methods for the treatment of obstructive sleep apnoea (osa)
US20260076984A1 (en) Treatment of behavioral impairment in developmental and epileptic encephalopathy
Takaesu et al. Effects of nasal continuous positive airway pressure on panic disorder comorbid with obstructive sleep apnea syndrome
CN116829135A (zh) 大麻二酚对睡眠呼吸暂停的治疗
US20240366635A1 (en) Treatment of seizure disorders
CN116782891A (zh) 大麻二酚对难治性癫痫发作的治疗
Shinno et al. Three patients with cancer who developed rapid-eye-movement sleep behavior disorder
Kim et al. Low-Dose Baclofen-Induced Encephalopathy in a Patient with End-Stage Renal Disease: A Case Report
Gupta et al. Idiopathic central sleep apnea: an Indian case with polysomnographic findings
Sixel-Döring et al. TL-098 POLYSOMNOGRAPHICALLY VALIDATED REM SLEEP BEHAVIOUR DISORDER IN RESTLESS LEGS SYNDROME: FREQUENCY AND ASSOCIATED FACTORS
SCHIZOAFFECTIVE Psych Rx

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Country or region after: U.S.A.

Address after: Pennsylvania, USA

Applicant after: Harmony Biological Science Management Co.,Ltd.

Address before: Pennsylvania, USA

Applicant before: Zyne pharmaceutical Co.

Country or region before: U.S.A.